Servier to build cancer drug pipeline with $2.5B purchase of Day One
Source: BioPharma Dive - Latest News
The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved therapy for certain hard-to-treat brain tumors that affect children.